









Markets
/
Stocks
/
nasdaq-ntla
/

Intellia Therapeutics Inc

NTLA

15.460USD

+3.050+24.58%

Market hours （ET）Quotes delayed by 15 min

1.60BMarket Cap

LossP/E TTM



Intellia Therapeutics Inc

15.460

+3.050+24.58%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated：2025-09-17

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a very weak market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

57 / 507

Overall Ranking

162 / 4723

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 26 analysts

Buy

Current Rating

34.136

Target Price

+178.21%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Intellia Therapeutics, Inc. is a clinical-stage genome editing company, which is focused on developing curative therapeutics using Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) technology. CRISPR/Cas9 is a technology for genome editing, the process of altering selected sequences of genomic deoxyribonucleic acid. It is focused on leveraging its modular platform to advance in vivo and ex vivo therapies for diseases with high unmet need. Its lead in vivo candidate, NTLA-2001, is for the treatment of transthyretin (ATTR) amyloidosis, as well as NTLA-2002 for the treatment of hereditary angioedema (HAE) are the first CRISPR/Cas9-based therapy candidates to be administered systemically, via intravenous (IV) infusion, for precision editing of a gene in a target tissue in humans. It is also developing ex vivo applications to address immuno-oncology and autoimmune diseases.

Growing

The company is in a growing phase, with the latest annual income totaling USD 57.88M.

Overvalued

The company’s latest PE is -2.65, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 102.48M shares, decreasing 13.63% quarter-over-quarter.

Held by Catherine Wood

Star Investor Catherine Wood holds 13.02M shares of this stock.

Financial Health

Currency: USD Updated：2025-09-17

The company's current financial score is 6.27, which is lower than the Biotechnology & Medical Research industry's average of 6.93. Its financial status is stable, and its operating efficiency is low. Its latest quarterly revenue reached 14.24M, representing a year-over-year increase of 104.76%, while its net profit experienced a year-over-year increase of 31.11%.

Score

Industry at a Glance

Previous score

6.27

Change



Financials

6.96

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.61

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

2.77

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

6.93

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.09

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated：2025-09-17

The company’s current valuation score is 2.80, which is lower than the Biotechnology & Medical Research industry's average of 3.06. Its current P/E ratio is -2.65, which is 17.00% below the recent high of -3.10 and -130.74% above the recent low of -6.11.

Score

Industry at a Glance

Previous score

2.00

Change

0.8

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 57/507

No Data

Earnings Forecast

Currency: USD Updated：2025-09-17

The company’s current earnings forecast score is 8.08, which is higher than the Biotechnology & Medical Research industry's average of 8.03. The average price target for Intellia Therapeutics Inc is 25.50, with a high of 106.00 and a low of 7.00.

Score

Industry at a Glance

Previous score

8.08

Change

Support & Resistance

No Data

Analyst Rating

Based on 26 analysts

Buy

Current Rating

34.136

Target Price

+175.07%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

Intellia Therapeutics Inc

NTLA

CRISPR Therapeutics AG

CRSP

Ionis Pharmaceuticals Inc

IONS

Exact Sciences Corp

EXAS

argenx SE

ARGX

IQVIA Holdings Inc

IQV

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated：2025-09-17

The company’s current price momentum score is 8.15, which is higher than the Biotechnology & Medical Research industry's average of 6.32. Sideways: Currently, the stock price is trading between the resistance level at 13.73 and the support level at 10.45, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.70

Change

1.45

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(1)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

0.171

Buy

RSI(14)

62.530

Neutral

STOCH(KDJ)(9,3,3)

65.514

Buy

ATR(14)

0.728

High Vlolatility

CCI(14)

221.660

Overbought

Williams %R

31.151

Buy

TRIX(12,20)

0.201

Sell

StochRSI(14)

100.000

Overbought

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

11.818

Buy

MA10

11.778

Buy

MA20

11.443

Buy

MA50

11.692

Buy

MA100

10.234

Buy

MA200

10.303

Buy

Institutional Confidence

Currency: USD Updated：2025-09-17

The company’s current institutional recognition score is 10.00, which is higher than the Biotechnology & Medical Research industry's average of 5.96. The latest institutional shareholding proportion is 98.83%, representing a quarter-over-quarter decrease of 3.67%. The largest institutional shareholder is Catherine Wood, holding a total of 13.02M shares, representing 12.13% of shares outstanding, with 1.48% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

ARK Investment Management LLC

Star Investors

13.01M

+3.79%

The Vanguard Group, Inc.

Star Investors

10.73M

+5.53%

BlackRock Institutional Trust Company, N.A.

8.41M

-4.67%

Two Sigma Investments, LP

3.98M

+3.11%

State Street Global Advisors (US)

4.51M

-13.36%

Regeneron Pharmaceuticals Inc

3.70M

Amova Asset Management Co., Ltd.

2.83M

-5.59%

Geode Capital Management, L.L.C.

2.48M

+3.81%

Risk Assessment

Currency: USD Updated：2025-09-17

The company’s current risk assessment score is 3.09, which is lower than the Biotechnology & Medical Research industry's average of 3.33. The company's beta value is 2.20. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.